An analysis of bone mass and remodeling in women with pharmacological inhibition of ovarian function. The response to nasal calcitonin

Pharmacological inhibition of ovarian function (PIOF) in young women is associated with hypoestrogenism and very low estrogen levels. These alterations can trigger osteopenia, either by delayed peak bone mass or by active bone destruction, and therefore, an increased risk of osteoporosis at later ye...

Full description

Saved in:
Bibliographic Details
Published inGinecologia y obstetricia de Mexico Vol. 62; p. 274
Main Authors Bori Segura, G, Tamayo y Orozco, J A, Onega Rosales, M del C, Valero Origel, A
Format Journal Article
LanguageSpanish
Published Mexico 01.09.1994
Subjects
Administration, Intranasal
Adult
Analysis of Variance
Bone Density - drug effects
Bone Diseases, Metabolic - chemically induced
Bone Diseases, Metabolic - drug therapy
Bone Diseases, Metabolic - physiopathology
Bone Remodeling - drug effects
Calcitonin - administration & dosage
Calcitonin - adverse effects
Depression, Chemical
Endometriosis - complications
Endometriosis - drug therapy
Endometriosis - physiopathology
Female
Humans
Leuprolide - administration & dosage
Leuprolide - adverse effects
Ovary - drug effects
Ovary - physiopathology
Prospective Studies
Online AccessGet full text

Cover

More Information
Summary:Pharmacological inhibition of ovarian function (PIOF) in young women is associated with hypoestrogenism and very low estrogen levels. These alterations can trigger osteopenia, either by delayed peak bone mass or by active bone destruction, and therefore, an increased risk of osteoporosis at later years. Twenty-one women (mean age: 32 years) with diagnosis of endometriosis, who were submitted to PIOF with leuprolide acetate, were prospectively studied. As a result of treatment for bone resorption with nasal spray salmon calcitonin, 200 UI/day, a decreased femoral and lumbar bone mass density was identified in these women through densitometry. Regarding bone remodelling biochemistry, changes were seen in urinary markers suggesting bone destruction inhibition, while bone formation markers showed stimulation. Biochemical markers of bone turnover and bone mass measurements are useful during follow-up of young women with osteopenia.
ISSN:0300-9041